Cardiff Oncology Announces Plans For A Randomized Trial, Durability Of Responses In Ongoing Phase 1b/2 Trial In Metastatic Colorectal Cancer And Additional Business Updates
Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expected in 2H